HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Prevention of thromboembolism in spinal fractures with spinal cord injuries. Standard heparin versus low-molecular-weight heparin in acute paraplegia].

Abstract
In a prospective, randomized, open study, the therapeutic efficacy of a long-term prophylaxis with standard heparin (SH) was compared with that of low-molecular-weight heparin (LMWH) Dalteparin in 166 patients who had spinal fractures with spinal cord injury. 86 patients were treated with SH 2 x 7500 U s.c. and 80 patients were treated with LMWH 1 x 5000 anti-Xa U s.c. once daily. The screening was implemented by daily bedside-examination. In case of clinical thromboembolism-symptoms patients had confirmatory venography or lung scans. In the SH-group 12 (14.0%) patients had deep vein thrombosis and in the LMWH-group 6 (7.5%). Pulmonary embolism was detected two times in the SH-group (2.33%) and only one time in the LMWH-group (1.25%). A significant difference could not be shown, but is descriptive evident.
AuthorsU Lohmann, E Gläser, B E Braun, U Bötel
JournalZentralblatt fur Chirurgie (Zentralbl Chir) Vol. 126 Issue 5 Pg. 385-90 (May 2001) ISSN: 0044-409X [Print] Germany
Vernacular TitleThromboembolieprophylaxe bei Wirbelsäulenfrakturen mit Rückenmarkverletzungen. Standard-Heparin versus niedermolekulares Heparin bei frischen Querschnittsyndromen.
PMID11396248 (Publication Type: Clinical Trial, Comparative Study, English Abstract, Journal Article, Randomized Controlled Trial)
Chemical References
  • Heparin, Low-Molecular-Weight
  • Heparin
Topics
  • Acute Disease
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Heparin (administration & dosage, adverse effects)
  • Heparin, Low-Molecular-Weight (administration & dosage)
  • Humans
  • Long-Term Care
  • Male
  • Middle Aged
  • Paraplegia (complications, drug therapy)
  • Prospective Studies
  • Spinal Cord Injuries (complications, drug therapy)
  • Spinal Fractures (complications, drug therapy)
  • Thromboembolism (etiology, prevention & control)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: